Denali Therapeutics Inc. (MUN:4DN)
Germany
· Delayed Price · Currency is EUR 19.54
+0.45 (2.33%)
At close: Feb 3, 2026
Denali Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | - | - | 330.53 | 108.46 | 48.66 | Upgrade
|
| Revenue Growth (YoY) | - | - | 204.74% | 122.89% | -85.50% | Upgrade
|
| Cost of Revenue | - | 396.44 | 423.88 | 358.73 | 265.35 | Upgrade
|
| Gross Profit | - | -396.44 | -93.35 | -250.27 | -216.69 | Upgrade
|
| Selling, General & Admin | 136.56 | 105.44 | 103.35 | 90.48 | 79.06 | Upgrade
|
| Research & Development | 418.78 | - | - | - | - | Upgrade
|
| Operating Expenses | 555.34 | 105.44 | 103.35 | 90.48 | 79.06 | Upgrade
|
| Operating Income | -555.34 | -501.88 | -196.7 | -340.74 | -295.75 | Upgrade
|
| Interest Expense | - | -0.3 | - | - | - | Upgrade
|
| Interest & Investment Income | 42.9 | 29.82 | 7.55 | 13.14 | 13.34 | Upgrade
|
| EBT Excluding Unusual Items | -512.44 | -472.36 | -189.15 | -327.61 | -282.41 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 35.12 | 43.95 | 1.64 | -8.75 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 14.54 | - | - | - | Upgrade
|
| Pretax Income | -512.44 | -422.71 | -145.19 | -325.97 | -291.16 | Upgrade
|
| Income Tax Expense | 0.1 | 0.07 | 0.03 | 0.02 | -0.58 | Upgrade
|
| Net Income | -512.54 | -422.77 | -145.22 | -325.99 | -290.58 | Upgrade
|
| Net Income to Common | -512.54 | -422.77 | -145.22 | -325.99 | -290.58 | Upgrade
|
| Shares Outstanding (Basic) | 173 | 164 | 137 | 126 | 122 | Upgrade
|
| Shares Outstanding (Diluted) | 173 | 164 | 137 | 126 | 122 | Upgrade
|
| Shares Change (YoY) | 4.97% | 19.73% | 9.43% | 3.30% | 7.83% | Upgrade
|
| EPS (Basic) | -2.97 | -2.57 | -1.06 | -2.60 | -2.39 | Upgrade
|
| EPS (Diluted) | -2.97 | -2.57 | -1.06 | -2.60 | -2.39 | Upgrade
|
| Free Cash Flow | -422.1 | -363.61 | -370.93 | -262.55 | -219.89 | Upgrade
|
| Free Cash Flow Per Share | -2.44 | -2.21 | -2.70 | -2.09 | -1.81 | Upgrade
|
| Gross Margin | - | - | -28.24% | -230.74% | - | Upgrade
|
| Operating Margin | - | - | -59.51% | -314.16% | -607.78% | Upgrade
|
| Profit Margin | - | - | -43.94% | -300.56% | -597.15% | Upgrade
|
| Free Cash Flow Margin | - | - | -112.22% | -242.06% | -451.88% | Upgrade
|
| EBITDA | -540.53 | -500.79 | -179.97 | -330.36 | -287.16 | Upgrade
|
| EBITDA Margin | - | - | -54.45% | - | - | Upgrade
|
| D&A For EBITDA | 14.81 | 1.09 | 16.73 | 10.38 | 8.59 | Upgrade
|
| EBIT | -555.34 | -501.88 | -196.7 | -340.74 | -295.75 | Upgrade
|
| EBIT Margin | - | - | -59.51% | - | - | Upgrade
|
| Revenue as Reported | - | - | 330.53 | 108.46 | 48.66 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.